Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294099 | 0.88 | CALM1 (0.55) | STAT3ATMKDM4EAOC3POLB | |
| SCHEMBL8294364 | 0.88 | CALM1 (0.63) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL10776243 | 0.86 | STAT3 (0.55) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL27817906 | 0.85 | STAT3 (0.63) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL15236787 | 0.85 | STAT3 (0.73) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL265633 | 0.85 | STAT3 (0.63) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL5145815 | 0.85 | STAT3 (0.50) | STAT3ATMKDM4EAOC3POLB | |
| SCHEMBL103861 | 0.85 | STAT3 (0.50) | STAT3ATMKDM4EAOC3CA2 | |
| SCHEMBL16047309 | 0.84 | STAT3 (0.49) | STAT3ATMKDM4EMAPTALDH1A1 | |
| SCHEMBL8294098 | 0.84 | SIGMAR1 (0.52) | STAT3ATMKDM4EAOC3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | AMRYT RESEARCH LIMITED (IE) | 2022-02-10 | — | — | US | disclosed |
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | NORTHWESTERN UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210186972-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
| US-11041069-B2 | Gene delivery carrier | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA | 2020-07-23 | — | — | US | disclosed |
| US-20190194444-A1 | GENE DELIVERY CARRIER | POLITECNICO DI MILANO (IT) | 2019-06-27 | — | — | US | disclosed |
| WO-2019111225-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS | AVALIV THERAPEUTICS (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20130040937-A1 | INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7514570-B2 | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (GnRH) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7491731-B2 | Crystal structure of liganded cFMS kinase domain | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | SHEWCHUK LISA M | 2007-01-11 | — | — | US | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | STAT3 2218/4885ATM 1473/4885KDM4E 2800/4885 |
| US-20190194444-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | STAT3 944/4885ATM 3091/4885KDM4E 2342/4885 |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | STAT3 1475/4885ATM 2331/4885KDM4E 956/4885 |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | TP53, BRCA1, MET | STAT3 318/4885ATM 1274/4885KDM4E 1965/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | STAT3 1475/4885ATM 2331/4885KDM4E 956/4885 |
| US-20210186972-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | FOXK1, FOXO1, FOXO3 | STAT3 47/4885ATM 3179/4885KDM4E 3297/4885 |
| US-20070010540-A1 | Crystal structure of liganded cFMS kinase domain | FAM20C, FRS2, FRK | STAT3 1149/4885ATM 347/4885KDM4E 4461/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | STAT3 28/4885ATM 284/4885KDM4E 3392/4885 |
| US-11041069-B2 | Gene delivery carrier | PAICS, PBDC1, BCAT1 | STAT3 944/4885ATM 3091/4885KDM4E 2342/4885 |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | SALL4, GLI2, TCF4 | STAT3 24/4885ATM 2363/4885KDM4E 1267/4885 |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | SALL4, GLI2, TCF4 | STAT3 24/4885ATM 2363/4885KDM4E 1267/4885 |
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | SQSTM1, ATG7, BECN1 | STAT3 1380/4885ATM 1326/4885KDM4E 3278/4885 |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | TK1, XPA, RNASE1 | STAT3 693/4885ATM 1702/4885KDM4E 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.